Clinical Trial · NCT06203587

Clinical Study of GPA33-specific PET/CT for the Diagnosis of Colorectal Cancer

Overview

In this study, we will first investigate the imaging safety and feasibility of \[68Ga\]Ga-NOTA-WWH347 and \[18F\]F-H3RESCA-WWH347 PET/CT in patients with primary and/or metastatic colorectal cancers. The second goal of the study is to preliminarily investigate the diagnostic efficacy (e.g., sensitivity and specificity) of \[68Ga\]Ga-NOTA-WWH347 and \[18F\]F-H3RESCA-WWH347 PET/CT in patients with primary and/or metastatic colorectal cancers. This study will provide a new method for the noninvasive target-specific diagnosis of colorectal cancer, and provide an intuitive and clear imaging basis for clinical diagnosis, differential diagnosis and treatment.

Sponsor

Huashan Hospital

Phase

N/A

Contacts

Fang Xie, PhD (PRINCIPAL_INVESTIGATOR)

Yihui Guan, MD (CONTACT)

guanyihui@hotmail.com

13764308300

ClinicalTrials.gov

NCT06203587

Drug / Compound

WWH347

Isotope(s):

Target(s):

GPA33

Ligand Class: Small Proteins and Antibody Fragments

Chelator: NOTA

WWH347

Isotope(s):

Target(s):

GPA33

Ligand Class: Small Proteins and Antibody Fragments

Chelator: H3RESCA

Eligibility

Inclusion

Patients with colorectal cancer confirmed by puncture or surgical pathology.

Exclusion

Liver function: bilirubin, AST(SGOT)/ALT(SGPT) less than or equal to the upper limit of the normal range.
History of serious surgery in the last month.
Targeted therapy before radiotherapy or PET/CT scan. Renal function: serum creatinine less than or equal to the upper limit of the normal range;
Severe hepatic or renal insufficiency;